General Information of the Drug (ID: M6APDG02383)
Name
TAK-960
Synonyms
TAK-960; 1137868-52-0; TAK960; TAK 960; CHEMBL2392545; AK172385; benzamide, 4-[(9-cyclopentyl-7,7-difluoro-6,7,8,9-tetrahydro-5-methyl-6-oxo-5h-pyrimido[4,5-b][1,4]diazepin-2-yl)amino]-2-fluoro-5-methoxy-n-(1-methyl-4-piperidinyl)-; 4-[(9-Cyclopentyl-7,7-Difluoro-5-Methyl-6-Oxo-6,7,8,9-Tetrahydro-5h-Pyrimido[4,5-B][1,4]diazepin-2-Yl)amino]-2-Fluoro-5-Methoxy-N-(1-Methylpiperidin-4-Yl)benzamide
    Click to Show/Hide
Status
Phase 1
Structure
Formula
C27H34F3N7O3
InChI
1S/C27H34F3N7O3/c1-35-10-8-16(9-11-35)32-24(38)18-12-22(40-3)20(13-19(18)28)33-26-31-14-21-23(34-26)37(17-6-4-5-7-17)15-27(29,30)25(39)36(21)2/h12-14,16-17H,4-11,15H2,1-3H3,(H,32,38)(H,31,33,34)
InChIKey
GWRSATNRNFYMDI-UHFFFAOYSA-N
PubChem CID
53357478
TTD Drug ID
D09JGK
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Polo-like kinase 1 (PLK1)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
Response Summary Polo-like kinase 1 (PLK1) is a therapeutic target for TAK-960. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of TAK-960 through regulating the expression of Polo-like kinase 1 (PLK1). [1], [2]
References
Ref 1 METTL3-mediated m(6)A modification regulates cell cycle progression of dental pulp stem cells. Stem Cell Res Ther. 2021 Mar 1;12(1):159. doi: 10.1186/s13287-021-02223-x.
Ref 2 J Clin Oncol 29: 2011 (suppl; abstr 3012).